Along 4 The Hike: Tifft Nature Preserve
BUFFALO, N.Y. (WIVB) — This week's hike is a 264-acre refuge dedicated to conservation and environmental education, right within the city limits. You're almost guaranteed to see deer on the trails.
The site was once a landfill site, but the City of Buffalo bought the land in 1972 and sealed off the waste. In 1982, Tifft became part of the Buffalo Museum of Science, which runs it to this day.
Address: 1200 Fuhrmann Boulevard, Buffalo, NY 14203
Difficulty: Medium
Learn more: Visit the Tifft Nature Preserve website and dig into the Western New York Hiking Challenge.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
19 hours ago
- Business Upturn
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 (150 mg Q4W) Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement ( > 8 point) in AAS7 at Week 52. 1 DermNet . About Barzolvolimab Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU Study The randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 Program Celldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU) CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under 'Risk Factors' in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337 [email protected]
Yahoo
21 hours ago
- Yahoo
Along 4 The Hike: Tifft Nature Preserve
BUFFALO, N.Y. (WIVB) — This week's hike is a 264-acre refuge dedicated to conservation and environmental education, right within the city limits. You're almost guaranteed to see deer on the trails. The site was once a landfill site, but the City of Buffalo bought the land in 1972 and sealed off the waste. In 1982, Tifft became part of the Buffalo Museum of Science, which runs it to this day. Address: 1200 Fuhrmann Boulevard, Buffalo, NY 14203 Difficulty: Medium Learn more: Visit the Tifft Nature Preserve website and dig into the Western New York Hiking Challenge. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 days ago
- Yahoo
Educators learn to use AI tools at Niswonger School Success Symposium
KINGSPORT, Tenn. (WJHL) – At this year's Niswonger Foundation School Success Symposium, teachers from around East Tennessee gathered to learn more about changing technology in the classroom, including the uses of AI. Niswonger Foundation CEO Steve Barnett said the topic of the symposium was chosen by the teachers attending. This year, Barnett said teachers decided to learn about how AI tools can be used in the classroom. 'It's emerging and it's going to continue to change over time,' Barnett said. 'And we want to make sure that it's something that teachers feel comfortable with because they see your students use it, teachers can use it and we want to make sure everybody has what they need to be able to be successful with our use of AI in the classroom.' 2024 National Teacher of the Year Missy Testerman spoke to over 600 teachers about how even though AI will change things, human connection with students will always be needed. Testerman said, for example, AI tools will not help students who may be nervous about a test. 'It is something that we're going to have to embrace because we want our students to be prepared for the future,' Testerman said. 'We just have to figure out a way to take in all the advantages that we can of ed tech while we maintain that spirit of humanity.' Live music, kids fishing day and more | Weekend events in the Tri-Cities Beth Zeisenis, also known as 'Beth Z, Your Nerdy Best Friend,' was this year's keynote speaker for the symposium. 'Teachers have such a tough time right now with the whole concept of AI and so what I tried to do was give them some tools that they can use right away, plus some bigger concepts about how it works and where it's going,' Zeisenis said. Zeisenis went through many AI programs including Chat GPT and Magic School Plus. She said teachers can use AI tools to complete small tasks such as making lesson plans. Zeisenis also said teachers need to have conversations with students about how to properly use AI instead of trying to stop students from using it altogether. 'We need to go into conversations with our students about trusting each other and about learning this together, because if we go in with a defensive posture, if we go in distrusting each other, then you have a challenge because it's there all the time,' Zeisenis SAID. 'It's going to be like calculators in our pockets. They're going to have it for the rest of their lives. So how can we teach students and each other how we can use that rather than being afraid of it or feeling like it's an affront to what's going on?' Zeisenis and Testerman both encourage East Tennessee teachers to talk to school administrators about the ways AI can be used in the classroom. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
